Lactobacillus brevis.

Glutamate decarboxylase converts glutamate into GABA, and this is one of the better characterised metabolic capabilities of selected L. brevis strains. It is a strain-level property, so a given commercial culture may or may not carry the functional gene. The reviews describing this are systematic and narrative summaries of microbial capability, not human outcome trials. Whether bacterially produced GABA in the gut reaches the brain in humans remains unsettled.

Bacterial GABA synthesis needs glutamate, and glutamine supplies the glutamate pool through glutaminase activity. Supplying more substrate is the standard route to raising fermentative output in vitro. Whether an oral glutamine dose changes luminal GABA production in a person has not been measured. Read it as mechanistic rather than clinical.

Pyridoxal-5-phosphate is the obligatory cofactor for every glutamate decarboxylase, which means bacterial GABA production depends on adequate B6 in the environment. This is settled enzymology rather than a supplement finding. It explains why fermentation media for GABA-producing cultures include a B6 source. It does not establish that taking B6 with the probiotic changes anything in a person.

Fructans arrive in the colon undigested by human enzymes and serve as fermentable substrate for saccharolytic bacteria including lactobacilli. Combining the substrate with the organism is the definition of a synbiotic. Fermentation capacity is strain-dependent, so not every L. brevis strain uses inulin equally well. The pairing is formulation logic supported by general microbiology.

Most probiotic products on the market are multi-strain, and the trials that include L. brevis generally test it inside such a blend rather than alone. That makes it difficult to attribute any result to this species specifically. Combining genera broadens the metabolic range of the product. The evidence supports the blend, not the individual component.

These two species co-occur naturally in sauerkraut, kimchi and sourdough cultures, so pairing them in a supplement mirrors an existing microbial community. They share acid tolerance and overlapping substrate preferences without excluding each other. Formulators combine them for that reason. The grounding is fermentation microbiology, not a controlled trial of the pair.

A yeast and a lactic acid bacterium occupy different niches and are combined on the reasoning that they compete with unwanted organisms by different routes. The supporting work here is in animals and concerns colonisation, a microbial endpoint. That is not a human clinical outcome. The combination is common in products but thinly evidenced as a pair.

Both a live culture and a supplemental enzyme have to survive gastric transit to do anything downstream, which is why products carrying both often use acid-resistant capsules or delayed release. The two do not compete chemically. The shared constraint is delivery. This is formulation practice rather than a functional interaction.

B vitamin handling is strain-specific among lactic acid bacteria, with some species requiring exogenous B12 and related vitamins for growth and others contributing to the gut vitamin pool. Without strain-level genomic data you cannot say which applies to a given culture. This is why fermentation media composition varies between manufacturers. Anyone reading a strain claim should check the designation, not the species name.

Gut lactobacilli metabolise tea catechins into smaller phenolic acids, and the polyphenols in turn affect which bacteria grow. The relationship is bidirectional and well described for the polyphenol class in general. The specific study available here is in broilers, an animal production setting. Read it as mechanistic background rather than human evidence.